Geode Capital Management LLC Acquires 94,870 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Geode Capital Management LLC boosted its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 7.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,425,827 shares of the biopharmaceutical company’s stock after acquiring an additional 94,870 shares during the quarter. Geode Capital Management LLC owned 2.45% of Vanda Pharmaceuticals worth $6,689,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC raised its position in shares of Vanda Pharmaceuticals by 128.2% during the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock worth $722,000 after acquiring an additional 86,677 shares during the last quarter. ClearAlpha Technologies LP grew its holdings in Vanda Pharmaceuticals by 50.0% during the 3rd quarter. ClearAlpha Technologies LP now owns 60,000 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 20,000 shares during the period. Verition Fund Management LLC raised its position in shares of Vanda Pharmaceuticals by 7.8% in the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 2,927 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Vanda Pharmaceuticals by 1,184.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 57,393 shares during the period. Finally, FMR LLC lifted its stake in shares of Vanda Pharmaceuticals by 25.9% in the 3rd quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after purchasing an additional 30,802 shares during the period. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the transaction, the director now directly owns 44,857 shares in the company, valued at $231,910.69. This trade represents a 10.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

VNDA has been the subject of a number of research analyst reports. StockNews.com began coverage on Vanda Pharmaceuticals in a report on Saturday. They issued a “hold” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report on Monday, December 23rd.

Vanda Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ VNDA opened at $4.85 on Friday. The firm has a market capitalization of $282.79 million, a P/E ratio of -17.32 and a beta of 0.77. The firm’s 50-day moving average price is $4.88 and its 200-day moving average price is $5.14. Vanda Pharmaceuticals Inc. has a 1-year low of $3.46 and a 1-year high of $6.75.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.